Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

FH535

Catalog No: tcsc1538

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
108409-83-2

Formula:
$C_{13}H_{10}Cl_2N_2O_4S$

Pathway:
Cell Cycle/DNA Damage;Stem Cell/Wnt;Stem Cell/Wnt

Target:
PPAR;β-catenin;Wnt

Purity / Grade:
>98%

Solubility:
DMSO : 33.33 mg/mL (92.28 mM; Need ultrasonic); H2O :

Observed Molecular Weight:
361.2

Product Description

FH535 is an inhibitor of **Wnt/β-catenin** and **PPAR**, with anti-tumor activities.

IC50 & Target: Wnt, β-catenin, PPAR[1]

In Vitro:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities depend on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway[1]. FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μM) inhibits pancreatic cancer cell invasion and cell growth[2]. FH535 represses angiogenesis-related genes in pancreatic cancer cells[3].

In Vivo: FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts[2].